SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Benyam D. Addissie, Lewis R. Roberts, Classification and Staging of Hepatocellular Carcinoma, Clinics in Liver Disease, 2015, 19, 2, 277

    CrossRef

  2. 2
    Haruhiko Takeda, Hiroki Nishikawa, Yukio Osaki, Kaoru Tsuchiya, Kouji Joko, Chikara Ogawa, Hiroyoshi Taniguchi, Etsuro Orito, Yasushi Uchida, Namiki Izumi, Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan, Liver International, 2015, 35, 5
  3. 3
    A Parish, M Schwaederle, G Daniels, D Piccioni, P Fanta, R Schwab, K Shimabukuro, BA Parker, T Helsten, R Kurzrock, Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics, Cell Cycle, 2015, 14, 13, 2121

    CrossRef

  4. 4
    Takeshi Yamada, Masato Abei, Inaho Danjoh, Ryoko Shirota, Taro Yamashita, Ichinosuke Hyodo, Yukio Nakamura, Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib, BMC Cancer, 2015, 15, 1

    CrossRef

  5. 5
    Yosuke Togashi, Hidetoshi Hayashi, Masato Terashima, Marco A de Velasco, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Kazuhiko Nakagawa, Kazuto Nishio, Inhibition of β-Catenin Enhances the Anticancer Effect of Irreversible EGFR-TKI in EGFR-Mutated Non–small-cell Lung Cancer with a T790M Mutation, Journal of Thoracic Oncology, 2015, 10, 1, 93

    CrossRef

  6. 6
    Valentina Vaira, Massimo Roncalli, Carlo Carnaghi, Alice Faversani, Marco Maggioni, Claudia Augello, Lorenza Rimassa, Tiziana Pressiani, Gaia Spagnuolo, Luca Di Tommaso, Stefano Fagiuoli, Elena Rota Caremoli, Massimo Barberis, Roberto Labianca, Armando Santoro, Silvano Bosari, MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma, Liver International, 2015, 35, 3
  7. 7
    Makoto Chuma, Katsuimi Terashita, Naoya Sakamoto, New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions, Hepatology Research, 2015, 45, 8
  8. 8
    Jiang Chen, Renan Jin, Jie Zhao, Jinghua Liu, Hanning Ying, Han Yan, Senjun Zhou, Yuelong Liang, Diyu Huang, Xiao Liang, Hong Yu, Hui Lin, Xiujun Cai, Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma, Cancer Letters, 2015, 367, 1, 1

    CrossRef

  9. 9
    Haruhiko Takeda, Hiroki Nishikawa, Yukio Osaki, Kaoru Tsuchiya, Kouji Joko, Chikara Ogawa, Hiroyoshi Taniguchi, Etsuro Orito, Yasushi Uchida, Namiki Izumi, Proposal of Japan Red Cross score for sorafenib therapy in hepatocellular carcinoma, Hepatology Research, 2015, 45, 8
  10. 10
    Roberto Ronca, Arianna Giacomini, Marco Rusnati, Marco Presta, The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis, Expert Opinion on Therapeutic Targets, 2015, 1

    CrossRef

  11. 11
    Roongruedee Chaiteerakij, Benyam D. Addissie, Lewis R. Roberts, Update on Biomarkers of Hepatocellular Carcinoma, Clinical Gastroenterology and Hepatology, 2015, 13, 2, 237

    CrossRef

  12. 12
    Hisashi Nishida, Etsuro Hatano, Koji Tomiyama, Satoshi Seo, Koujiro Taura, Yasuhiro Fujimoto, Masaki Mizumoto, Shinji Uemoto, A case of desensitization of sorafenib after tumor lysis syndrome and erythema multiform in the patient with advanced hepatocellular carcinoma, Kanzo, 2014, 55, 4, 221

    CrossRef

  13. 13
    Dalbir S. Sandhu, Esha Baichoo, Lewis R. Roberts, Fibroblast growth factor signaling in liver carcinogenesis, Hepatology, 2014, 59, 3
  14. 14
    Kazuyo Yasuda, Toshihiko Torigoe, Tasuku Mariya, Takuya Asano, Takafumi Kuroda, Junichi Matsuzaki, Kanae Ikeda, Makoto Yamauchi, Makoto Emori, Hiroko Asanuma, Tadashi Hasegawa, Tsuyoshi Saito, Yoshihiko Hirohashi, Noriyuki Sato, Fibroblasts induce expression of FGF4 in ovarian cancer stem-like cells/cancer-initiating cells and upregulate their tumor initiation capacity, Laboratory Investigation, 2014, 94, 12, 1355

    CrossRef

  15. 15
    Silvia Vilarinho, Diego F. Calvisi, New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment, Hepatology, 2014, 60, 6
  16. 16
    Antoine Galmiche, Bruno Chauffert, Jean-Claude Barbare, New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma, Cancer Letters, 2014, 346, 2, 159

    CrossRef

  17. 17
    Henning Wege, Tim H. Brümmendorf, Carlo Gambacorti-Passerini, A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma, Hepatology, 2013, 57, 4
  18. 18
    Daisuke Miyaki, Hiroshi Aikata, Hiromi Kan, Hatsue Fujino, Ayako Urabe, Keiichi Masaki, Takayuki Fukuhara, Tomoki Kobayashi, Noriaki Naeshiro, Takashi Nakahara, Tomokazu Kawaoka, Akira Hiramatsu, Shoichi Takahashi, Masaki Ishikawa, Hideaki Kakizawa, Kazuo Awai, Kazuaki Chayama, Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy, Journal of Gastroenterology and Hepatology, 2013, 28, 12